AGEN missed EPS expectations by 71.27%
Aug 08, 2024, 11:31 AM
0.00%
What does AGEN do
Agenus, Inc., a clinical-stage company based in Lexington, Massachusetts, specializes in developing technologies to treat cancers and infectious diseases, employing 533 full-time staff. The company, public since 2000, focuses on immune system therapies, including botensilimab and balstilimab, and has multiple clinical trials underway.
Agenus (AGEN) reported a negative EPS surprise in its most recent quarterly earnings. For the most recent quarter, Agenus's actual EPS was -$2.52, missing the estimate of -$1.47 per share, resulting in a -71.27% surprise.
📡️ Health Care
Earnings Surprise
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.